These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 4116282)

  • 21. Avian thrombocyte aggregation and shape change in vitro.
    Grant RA; Zucker MB
    Am J Physiol; 1973 Aug; 225(2):340-3. PubMed ID: 4198614
    [No Abstract]   [Full Text] [Related]  

  • 22. [Thrombocyte IIb/IIIa receptor inhibitors--a new direction in antithrombotic therapy].
    Panchenko EP
    Ter Arkh; 1997; 69(9):66-71. PubMed ID: 9411833
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibition and reversal of ristocetin - induced platelet aggregation.
    Howard MA
    Thromb Res; 1975 Jun; 6(6):489-99. PubMed ID: 239463
    [No Abstract]   [Full Text] [Related]  

  • 24. The clearing factor lipase (CFL) response to synthetic sulfonated polysaccharides in the rat.
    Monkhouse FC; Abbott EC
    Can J Physiol Pharmacol; 1966 Jul; 44(4):635-40. PubMed ID: 4165216
    [No Abstract]   [Full Text] [Related]  

  • 25. [Serum lipids following experimental fibrinolysis].
    Suschke J; Kunze D; von Pilar CE; Krejci K
    Monatsschr Kinderheilkd (1902); 1973 Jul; 121(7):388-9. PubMed ID: 4270871
    [No Abstract]   [Full Text] [Related]  

  • 26. [In-vitro thrombocyte aggregation due to cold].
    Krankenhagen B; Mann H; Hirsch H
    Pflugers Arch; 1972; 334(1):62-73. PubMed ID: 4626627
    [No Abstract]   [Full Text] [Related]  

  • 27. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
    Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
    Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clearing and anti-platelet-aggregation effects of a heparinoid of natural origin].
    Marini U; Bastoni F; Gibelli A
    Clin Ter; 1974 Oct; 71(1):13-31. PubMed ID: 4138995
    [No Abstract]   [Full Text] [Related]  

  • 29. Synthesis and non-thrombogenicity of heparinoid polyurethaneureas.
    Ito Y; Iguchi Y; Imanishi Y
    Biomaterials; 1992; 13(3):131-5. PubMed ID: 1373659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia.
    Elalamy I; Lecrubier C; Potevin F; Abdelouahed M; Bara L; Marie JP; Samama M
    Thromb Haemost; 1995 Nov; 74(5):1384-5. PubMed ID: 8607131
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hyperaggregation effects of thrombolytic enzymes].
    Brochier M; Griguer P
    Therapeutique; 1973 Nov; 49(9):565-6. PubMed ID: 4792901
    [No Abstract]   [Full Text] [Related]  

  • 32. Letter: Experimental model for von Willebrand's disease.
    Meyer D; Jenkins CS; Dreyfus M; Larrieu MJ
    Nature; 1973 Jun; 243(5405):293-4. PubMed ID: 4542702
    [No Abstract]   [Full Text] [Related]  

  • 33. Thrombogenicity of polysaccharide-coated surfaces.
    Keuren JF; Wielders SJ; Willems GM; Morra M; Cahalan L; Cahalan P; Lindhout T
    Biomaterials; 2003 May; 24(11):1917-24. PubMed ID: 12615482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Inhibition of platelet function (mode of action of platelet inhibitors) (author's transl)].
    Baumgartner HR
    Ther Umsch; 1977 May; 34(5):341-6. PubMed ID: 867315
    [No Abstract]   [Full Text] [Related]  

  • 35. Some side effects of heparin, heparinoids, and their antagonists.
    Coon WW; Willis PW
    Clin Pharmacol Ther; 1966; 7(3):379-98. PubMed ID: 4160815
    [No Abstract]   [Full Text] [Related]  

  • 36. [Use of the thromboelastograph for registration of the time of euglobulin lysis in normal rats and those with experimentally modified fibrinolysis].
    Prino G; Mantovani M; Butti A
    Farmaco Prat; 1969 Sep; 24(9):552-61. PubMed ID: 4187112
    [No Abstract]   [Full Text] [Related]  

  • 37. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins.
    Messmore HL; Griffin B; Koza M; Seghatchian J; Fareed J; Coyne E
    Semin Thromb Hemost; 1991; 17 Suppl 1():57-9. PubMed ID: 1712512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Paroxysmal nocturnal hemoglobinuria: inhibition of in vitro hemolysis by germanin, heparin and heparinoids].
    Schmid JH
    Schweiz Med Wochenschr; 1966 Sep; 96(38):1267-9. PubMed ID: 4169565
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.
    de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF
    Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin effects on irreversible platelet aggregation.
    Besterman EM; Gillett MP
    Lancet; 1972 Aug; 2(7771):282-3. PubMed ID: 4114537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.